Germany approves Photofrin

17 Jun 2002

Germany's health authorities have given approval for QLT Photo Therapeutics to market Photofrin, which is used in photodynamic therapy to treatearly-stage lung cancers. Beaufor Ipsen Group, which signed a marketing agreement with QLT last year, will market the drug in Europe. Photofrin will beused specifically for curing patients with early-stage endobronchial large-cell lung cancer who are not undergoing surgery or radiotherapy. (courtesy LaserFocus World)